Earnings call transcript: Alvotech misses Q1 2026 earnings, stock dips By Investing.com

Alvotech reported Q1 2026 EPS of -$0.09, well below the $0.0015 forecast, on revenue of $106 million versus $130.89 million expected; shares fell 7.28% premarket to $3.31. Revenue declined 20% year over year as manufacturing slowdowns at Reykjavik reduced throughput, though adjusted EBITDA improved to $24 million from $21 million and gross margin edged up to 57%. Management said FDA remediation is progressing, pending BLAs should be resubmitted in Q2, and the company still targets stronger performance in Q4 2026 and positive free cash flow by year-end.

Analysis

The market is reacting to a near-term execution problem, but the more important signal is that the company is deliberately trading current throughput for regulatory de-risking. That typically compresses the stock twice: first on the revenue miss, then again if investors start discounting the credibility of the back-half recovery. The key second-order effect is on working capital and cash conversion — when product shipments are throttled while fixed costs and cash interest stay sticky, even “good” gross margin math can coexist with a weaker equity story.

The cleaner beneficiary is TEVA. If the main growth engine is shifting toward a partner-led U.S. franchise while the manufacturer is capacity-constrained, TEVA gets operating leverage without bearing the same regulatory/manufacturing headline risk. More broadly, a U.S. manufacturing hedge is strategically rational, but the lag to first supply means the market should not capitalize that as a 2026 earnings fix; it is a 2027 option on supply resilience, not an immediate P&L bridge.

Contrarianly, the selloff may be partially overdone if the inspection closes cleanly and management can reframe the quarter as an investment period rather than an operational failure. The bigger swing factor over the next 1-2 quarters is not demand, which appears intact, but whether the company can prove uninterrupted resubmission timing and avoid another production interruption. If that happens, the stock can re-rate sharply off a very low base because expectations are now anchored to a worst-case regulatory overhang.

The real tail risk is that the remediation path slips from a 1-2 quarter issue into a multi-quarter credibility problem, which would force the market to question both launch timing and cash burn into 2027. In that scenario, equity upside from the current valuation is irrelevant because dilution risk becomes the dominant variable. Any sign of another delay in the BLA package or a second inspection issue would likely reset the narrative from ‘temporary slowdown’ to ‘structural execution discount.’

Key Decisions for Investors

• Short ALVO tactically into any relief rally over the next 1-3 trading days; cover if management confirms inspection close-out and a firm resubmission window, as the stock can squeeze on de-risking news.
• Long TEVA vs short ALVO as a 1-3 month pair trade: TEVA captures the commercial upside from the biosimilar ramp while ALVO carries the manufacturing/regulatory overhang; use a 1:1 notional pair and take profit if ALVO re-rates on inspection closure.
• Sell ALVO upside via call overwrites or short-dated call spreads into the next 4-8 weeks; the implied recovery path looks too linear, and the biggest positive catalyst is binary rather than trendable.
• If staying long ALVO, size it as a catalyst trade only and hedge with a small put spread into the resubmission/inspection window; risk is asymmetrically to the downside if timing slips again.
• Watch for a close above the post-earnings gap level after inspection news; that would be the first signal the market is willing to price 2H26 normalization rather than just 2027 optionality.